Who is sponsoring NCT03480529?

NCT03480529 is sponsored by Groupe Hospitalier Pitie-Salpetriere.

What drugs are being tested in NCT03480529?

Interventions in NCT03480529: drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom.

What condition does NCT03480529 study?

NCT03480529 studies Arthritis, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Capillary Leak Syndrome, Hepatitis.

Is NCT03480529 still recruiting?

NCT03480529 is currently completed. Last updated 4 September 2019.

Last reviewed 2019-09-04 · How we verify

NCT03480529: MIMUTOX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Monitoring the IMmUological TOXicity of Drugs

Completed Last updated 4 September 2019

What this trial tests

trial testing drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom in Arthritis in 662 participants. Completed in 10 March 2018.

Timeline

1 March 2018

Primary endpoint
10 March 2018

10 March 2018

Quick facts

Lead sponsor	Groupe Hospitalier Pitie-Salpetriere
Status	Completed
Study type	OBSERVATIONAL
Enrollment	662
Start date	1 March 2018
Primary completion	10 March 2018
Estimated completion	10 March 2018
Sites	2 locations across France

Drugs / interventions tested

drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom — full drug profile →

Conditions studied

Arthritis — all drugs for Arthritis →
Systemic Lupus Erythematosus — all drugs for Systemic Lupus Erythematosus →
Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
Capillary Leak Syndrome — all drugs for Capillary Leak Syndrome →

Sponsor

Groupe Hospitalier Pitie-Salpetriere

Who can join

18 and older, any sex, with Arthritis or Systemic Lupus Erythematosus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Several drugs and chemotherapies seem to have an impact on the immunological system. This study investigates reports of immunological toxicities, including the International classification of disease ICD-10 codes M05, M32, I78 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database.
Arnaud L, Mertz P, Gavand PE, Martin T, et al · · 2019 · cited 49× · PMID 30793701 · DOI 10.1136/annrheumdis-2018-214598

Verify or expand the search:

Other recruiting trials for Arthritis

Currently open trials in the same condition.

NCT05067998 — The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature · recruiting
NCT07284563 — Ultralow Dose PET Imaging for 18F-NaF Uptake · Phase 2 · recruiting
NCT06915012 — Impact of Biophoton Therapy on Chronic Severe Arthritis Pain · NA · recruiting
NCT06880653 — Dose Response of Exercise for Arthritis Management · NA · recruiting
NCT07106931 — Early STratification of Acute ARThritis · recruiting

Other Groupe Hospitalier Pitie-Salpetriere trials

Trials by the same sponsor.

NCT06515678 — Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension · active not recruiting
NCT05934214 — EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Databa · completed
NCT05819736 — Pharmacokinetics Study Of Rivaroxaban and Apixaban in Cancer Patients · unknown
NCT04320017 — Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observa · completed
NCT04314817 — Adverse Events Related to Treatments Used Against Coronavirus Disease 2019 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03480529 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Groupe Hospitalier Pitie-Salpetriere
Last refreshed: 4 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03480529.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing